Chemours (CC) just launched two new low global warming potential refrigerants, Opteon ZE and Opteon 515B, aimed at large stationary chillers that serve energy intensive AI and data center infrastructure.

Chemours shares trade at US$15.69, with a year to date share price return of 28.08%. This contrasts with a 26.58% decline over the past 90 days and a 45.90% fall in the 3 year total shareholder return. This points to improving short term momentum but a mixed longer term record as the market weighs new products like Opteon ZE and Opteon 515B against past setbacks.

If this AI cooling story has your attention, it may be worth broadening your research through a screener focused on data center and compute infrastructure. Start by scanning 55 AI infrastructure stocks

After a sharp year to date rebound but a weak multi year record, the question for Chemours is whether the real upside is still in front of investors or if the stock has already used up most of its recovery.

Most Popular Narrative: 20.7% Undervalued

The most followed Chemours narrative places fair value at $19.78 compared with the last close at $15.69, framing the recent AI cooling news within a broader recovery story.

Acceleration in regulatory-driven adoption of low global warming potential refrigerants is boosting sustained demand for Chemours' Opteon franchise, recent strong net sales and high margins signal that continued market share gains and capacity expansions will drive robust revenue and EBITDA growth through and beyond the 2025 and 2026 transition periods.

Want to see what underpins that refrigerant growth story and fair value gap? The key drivers are revenue mix, margin rebuild and the earnings multiple baked into these projections.

Result: Fair Value of $19.78 (UNDERVALUED)

However, the Chemours narrative can quickly change if PFAS litigation costs rise further or if competitive pressure in titanium dioxide and refrigerants weighs on pricing and margins.

Next Steps

If this balanced mix of risks and rewards around Chemours has you thinking, act quickly and review the details for yourself with 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Chemours?

If Chemours has sparked your interest, do not stop here. Use the Simply Wall Street Screener to compare other stocks, sharpen your watchlist and stay ahead.

• Zero in on value opportunities by scanning companies highlighted in the 50 high quality undervalued stocks that may offer a more attractive entry point.
• Prioritise resilience and sleep easier at night by reviewing stocks in the 78 resilient stocks with low risk scores that score well on risk factors.
• Get ahead of the crowd by checking the screener containing 18 high quality undiscovered gems that combine strong fundamentals with lower visibility among investors.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.